Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

NSE - NSE Delayed Price. Currency in INR
760.00+4.75 (+0.63%)
As of 1:23 AM EDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close755.25
Bid760.00 x
Ask760.10 x
Day's Range746.60 - 760.90
52wk Range704.00 - 933.95
1y Target EstN/A
Market Cap1.83T
P/E Ratio (ttm)29.54
Avg Vol (3m)3,682,921
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Reuters17 days ago

    India's Sun Pharma Q1 profit boosted by Gleevec generic

    Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported a quarterly profit that beat analysts' estimates, helped by its exclusive launch of the first generic version of leukaemia drug Gleevec in the United States. Net profit for the April-June quarter was 20.34 billion rupees ($304.17 million). Sun had reported a profit of 5.56 billion rupees a year ago, hurt by a big charge related to remediation costs at its drug factories.

  • Bloomberg17 days ago

    U.S. Cancer Drug Sales Helps Billionaire’s Sun Triple Profit

    Sun Pharmaceutical Industries Ltd. reported quarterly profit that more than tripled from a year earlier as its exclusive right to sell the generic version of Novartis AG’s blockbuster cancer drug Gleevec ...

  • Business Wire21 days ago

    Sun Pharma Extends Imatinib Mesylate Savings Card Program Benefits for Patients in USA

    As part of the company’s philosophy of putting patients' interests first, Sun Pharma announced the extension of its Imatinib Mesylate Savings Card Program beyond July 31, 2016.